Table 4.
Economic analysis comparing the cost‐effectiveness of prescribing choice
| Control | Metformin + SU | Control | Metformin + TZD | Control | Metformin + DPP‐4 inhibitor | |
|---|---|---|---|---|---|---|
| Absolute results | ||||||
| Total costs, £ | 19 228 | 19 507 | 18 550 | 18 345 | 18 599 | 21 289 |
| Total QALYs | 5.34 | 5.36 | 5.73 | 5.81 | 5.48 | 5.61 |
| Total life years | 7.98 | 8.15 | 8.54 | 8.63 | 8.25 | 8.39 |
| Incremental results (versus control) | ||||||
| Costs, £ | 279 | −205 | 2690 | |||
| QALYs | 0.02 | 0.07 | 0.13 | |||
| Life years | 0.17 | 0.09 | 0.15 | |||
| Cost‐effectiveness | ||||||
| Cost/QALY, £ | 17 640 | −2787 | 21 318 | |||
| Probability CE (%) at: £20k, £30k | 51, 54 | 75, 74 | 48, 61 | |||
Abbreviations: CE, cost‐effective; k: thousand.
“Control” is the same profile as intervention arm but no treatment effects.